+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO



Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO



Der Urologe. Ausg. a 56(2): 243-244




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060088360

Download citation: RISBibTeXText

PMID: 28144693

DOI: 10.1007/s00120-017-0329-0


Related references

Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. International Journal of Hyperthermia 23(5): 451-456, 2007

Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. European Urology 70(4): 684-691, 2016

Adjuvant hormonal therapy with goserilin improves survival in patients with locally advanced prostate cancer treated with radiotherapy Results of phase III randomized trial of the EORTC radiotherapy and genito-urinary tract cancer cooperative groups. Journal of Urology 159(5 Suppl. ): 131, 1998

Late urinary retention when using high dose rate prostate brachytherapy as a boost in local and locally advanced prostate cancer. International Journal of Radiation Oncology*biology*physics 60: S573-S574, 2004

Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy. PhytoTherapy Research 2018, 2018

The importance of local control in high-risk locally advanced prostate cancer. Current Oncology 19(Suppl 3): S6-S12, 2013

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16): 3670-3679, 2009

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. Bmc Cancer 18(1): 354, 2018

Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109(5): 858-867, 2007

First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO. Der Urologe. Ausg. a 56(10): 1331-1332, 2017

Endocrine treatment with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Yearbook of Oncology 2010: 91-92, 2010

Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomized trial. Bju International 2019, 2019

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. RadioTherapy and Oncology 76(1): 4-10, 2005

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 115(4): 784-791, 2009

Neoadjuvant docetaxel and capecitabine in patients with high risk/locally advanced prostate cancer: Preliminary results of a phase II study. Journal of Clinical Oncology 23(16_Suppl): 4742-4742, 2016